Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

Consider prescribing DUPIXENT for your patients with
uncontrolled moderate-to-severe AD

  • DUPIXENT may be prescribed to patients aged 12 years or older with moderate-to-severe AD whose disease is not adequately controlled with TCS who are candidates for systemic therapy1
  • DUPIXENT may be an appropriate choice for patients who are struggling to control their disease1
  • DUPIXENT can be used with or without TCS1

MICHAEL

Chronic, long-term, persistent disease

  • 47 years old, diagnosed in early childhood
  • Moderate-to-severe AD
  • Lichenified lesions frequently infected
  • Persistent itch, sleep loss

EASI score: 25

Current treatment:
Methotrexate

DLQI: 15

Prior treatments:
Failed rounds of ciclosporin

MICHAEL

Impact

  • Repeated antibiotic use
  • Feels conscious of his appearance in public
  • Persistent severe itch
  • Frequent sleep loss affects work performance and family life

Clinical assessment:

Lacks long-term disease control with current treatment

MICHAEL

Treatment goals

  • Reduce itching
  • Heal skin lesions
  • Improve his quality of life, including sleep
  • Spend less time on therapies requiring a frequent follow-up and lab monitoring

Illustrative patient profiles, not actual patients.

SHANNON

Moderate disease, with flares

  • 26 years old, diagnosed in early childhood Moderate AD
  • Troublesome flares
  • Sore lesions and itch
  • Sleep disturbance

EASI score: 16

Current treatment:
Topical corticosteroids

DLQI: 20

Prior treatments:
Non-responder to ciclosporin

SHANNON

Impact

  • Painful lesions in flexural areas
  • Lack of sleep causing fatigue which impacts daily life, including social activities
  • Feels anxious from the lack of AD control
  • Frustrated with not being able to control her disease

Clinical assessment:

Inadequate clinical improvement with current treatment

SHANNON

Treatment goals

  • Reduce itching
  • Heal skin lesions
  • Find a long-term treatment that adequately controls her disease
  • Find a treatment that allows her to get on with everyday life

Illustrative patient profiles, not actual patients.

GEORGE

Chronic, long-term, persistent disease

  • 15 years old, diagnosed eight years ago
  • Moderate-to-severe AD
  • Intense lesions and itch

EASI score: 30

Current treatment:
Topical corticosteroids

DLQI: 20

Prior treatments:
Non-responder to ciclosporin

GEORGE

Impact

  • Highly visible lesions on face have an impact on social life
  • Itch distracts him during lessons and keeps him up at night
  • Eight prolonged school absences this year due to disease
  • Experiences bullying due to disease with serious implication for his mental health

Clinical assessment:

Inadequate clinical improvement with current treatment

GEORGE

Treatment goals

  • Reduce itching
  • Heal skin lesions
  • Become less distracted by his symptoms and get a good night’s rest
  • Reduce the number of days taken off school

Illustrative patient profiles, not actual patients.

Patients like Michael, Shannon
and George can benefit from
treatment with DUPIXENT

  • DUPIXENT provides rapid and sustained improvements versus placebo in lesion extent and severity, pruritus intensity and quality-of-life measure1–4
  • DUPIXENT has demonstrated a consistent safety profile in clinical studies in adults and adolescents1

AD, atopic dermatitis; IL, interleukin.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: December 2020.
  2. Blauvelt A, et al. Lancet. 2017;389(10086):2287–2303.
  3. de Bruin-Weller, et al. Clinically Meaningful Responses in Moderate-to-Severe Atopic Dermatitis Patients Treated With Dupilumab presented at the 27th European Academy of Dermatology and Venerology Congress, Paris, France, September 12–16 2018.
  4. Paller A, et al. Dupilumab for Adolescents With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 3, Randomized, Double-Blinded Trial (Poster 10051) presented at the 77th annual meeting of the American Academy of Dermatology, Washington, DC, USA, March 1–5 2019.